Compare Inovio Pharmaceuticals Inc (INO) vs TeraWulf Inc (WULF) Price & Performance

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.

TeraWulf (WULF) trades at $13.73, down 4.65% today, amid a challenging fundamental backdrop with significant losses and negative margins. The stock shows technical bearish signals with moving averages indicating selling pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights the company's pivot to AI data center operations, with positive analyst coverage despite poor financial performance.

While analyst consensus remains strongly bullish with a $34.92 price target, fundamental weaknesses including negative net income margin of -1,179.94% and high valuation ratios present substantial risks. The company's transition to AI hosting offers growth potential but requires careful monitoring of cash flow sustainability and competitive positioning in the evolving data center market.